Osteoarthritis Therapeutics Market

Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies),Purchasing Pattern (Prescription Drugs) - Global Forecast to 2025

Report Code: PH 7393 Dec, 2020, by marketsandmarkets.com

[201 Pages Report] The osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025. The presence of a large geriatric and target patient population and the improving healthcare infrastructure in several APAC countries are expected to offer growth opportunities in the market during the forecast period.

Attractive Opportunities in Osteoarthritis Therapeutics Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID -19 Impact on the Osteoarthritis Therapeutics Market 

The market for osteoarthritis therapeutics is anticipated to be marginally affected due to the outbreak of COVID-19. Among drug types, the use of corticosteroids has reduced. Although there is no evidence to suggest that corticosteroid injections lead to a substantial increase in the risk of infection, there is a possible reduction in the immune response for up to a few weeks following the procedure. While this risk is extremely low, it needs to be considered when deciding to proceed with the procedure.

It should also be noted that the WHO, in one of its guidelines for the management of severe acute respiratory infection in patients with coronavirus, suggested avoiding systemic corticosteroids. 

Market Dynamics

DRIVER: Rising government investments in cell-based research significant adoption of pain medications

Topical, oral, and parenteral pain medications are widely used to manage pain associated with osteoarthritis. Although alternatives such as orthopedic braces are used as part of a noninvasive approach for pain management, the adoption of pain medications for the condition is high owing to the ease of administration and the affordability of pain medications. Pain relievers such as oral analgesics (acetaminophen and NSAIDs such as ibuprofen, naproxen, tramadol, opiates, and duloxetine), topical agents (such as capsaicin and topical NSAIDs), intra-articular agents (such as corticosteroids and hyaluronic acid), and nutraceuticals (glucosamine and chondroitin) are widely used. Studies reveal that these medications offer a 30% reduction of chronic pain on administration.

The adoption of pain medications for the management of pain associated with osteoarthritis is expected to remain high over the coming decade, which is anticipated to propel the growth of the market during the study period.

RESTRAINTS:Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment

OTC and prescription NSAIDs are widely used to relieve pain in osteoarthritis patients. As per a study published by the National Center for Biotechnology Information in 2019, more than 50% of osteoarthritis patients in the US are prescribed NSAIDs. Similarly, in Europe, of the total number of osteoarthritis patients using prescription medications (47%), 60% received NSAIDs.

The use of NSAIDs is associated with an increased risk of adverse cardiovascular events. Both cyclooxygenase (COX)-2 selective NSAIDs (coxibs) and non-selective NSAIDs increase CVD risk in patients. A study presented at the Annual European Congress of Rheumatology (EULAR 2018) stated that more than two-thirds of the increased cardiovascular risk associated with osteoarthritis is linked to NSAIDs. Such risks associated with the use of NSAIDs can potentially discourage doctors from prescribing these medications while driving patients using OTC NSAIDs to opt for alternative products.

OPPORTUNITY: Personalized medicine for osteoarthritis

Remarkable advances have been made in diagnosing, treating, and monitoring disease activity in patients with osteoarthritis, including the conceptualization of personalized OA medications. Essential features of biomarkers that will have clinical relevance for a personalized approach to therapy for RA include the ease of measurement, acceptable levels of sensitivity and specificity, and test methods that are accessible and interpretable by clinicians. The use of biomarkers to identify patients who are likely to respond to specific medical therapies may increase treatment response rates and reduce the risk of exposure to therapies that are unlikely to be effective or expose patients to serious treatment-related side-effects. The combination of unique biomarkers and baseline clinical characteristics such as sex and age may further enhance efforts to personalize treatment regimens for RA. 

“Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020.”

Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics. Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market. This can primarily be attributed to the high incidence of knee osteoarthritis.

“Viscosupplementation agents is expected to hold the largest share of the osteoarthritis therapeutics market, in 2020.”

Based on drug type, the market is classified as, viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is subsegmented into duloxetine and acetaminophen, while the NSAIDs segment is subsegmented into naproxen, aspirin, diclofenac, ibuprofen, and other NSAIDs. The viscosupplementation agents segment accounted for the largest share of the osteoarthritis therapeutics market in 2019. The rising incidence of knee osteoarthritis is the major factor driving the growth of this segment. Viscosupplementation effectively eases the pain of osteoarthritis through injections that fill up the joint’s synovial fluid, thus offering better lubrication of the joints. 

“Parental route is expected to hold the largest share of the osteoarthritis therapeutics market in 2020.”

On the basis of route of administration, the osteoarthritis therapeutics market has been segmented into oral, topical, and parenteral routes. The parenteral route accounted for the largest share of this market in 2019 and is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the wide adoption of the parenteral route for administering osteoarthritis therapeutics owing to the ease of administration and the better pharmacokinetics and pharmacodynamics, resulting in better patient compliance.

“Hospital pharmacies segment commanded the largest share of the osteoarthritis therapeutics market in 2020.”

Based on the distribution channel, the osteoarthritis therapeutics market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. In 2019, hospital pharmacies accounted for the largest share of this market because of the high volume of patients visiting hospitals for osteoarthritis treatments and the wide range of osteoarthritis therapeutics available in these pharmacies. Reimbursements can also be claimed easily on hospital pharmacy purchases, which is another important draw. 

“Prescription drugs segment commanded the largest share of the osteoarthritis therapeutics market in 2020.”

Based on the purchasing pattern, the osteoarthritis therapeutics market is segmented into OTC and prescription drugs. In 2019, the prescription drugs segment accounted for a larger share of this market as most osteoarthritis therapeutics (viscosupplementation agents and corticosteroids) are only available on prescription. 

Osteoarthritis Therapeutics Market By Region

To know about the assumptions considered for the study, download the pdf brochure

“Europe commanded the largest share of the osteoarthritis therapeutics market in 2020.”

On the basis of region, the osteoarthritis therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, Europe commanded the largest share of the osteoarthritis therapeutics market. The large share of this market segment can be attributed to the rising incidence of osteoarthritis, rising geriatric population, and increasing obesity rates in several European countries, coupled with the rising number of injuries due to sports and road accidents. 

Key Market Players

The major players operating in this market are Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India), Kitov Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi Pharm. Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain).

Scope of the report

Report Metric

Details

Market Size Available for Years

2018–2025

Base Year Considered

2019

Forecast Period

2020–2025

Forecast Units

Value (USD Billion)

Segments Covered

Anatomy, drug type, route of administration, prescription pattern, distribution channel, and region

Geographies Covered

North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and the RoE), APAC (Japan, China, Australia, South Korea, and the RoAPAC), and Rest of the World (Latin America and Middle East and Africa).

Companies Covered

Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India), Kitov Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi Pharm. Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain)

This research report categorizes the osteoarthritis therapeutics market into the following segments and sub segments:

Osteoarthritis Therapeutics by Anatomy

  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis

Osteoarthritis Therapeutics by Drug Type

  • Viscosupplementation Agents
  • Nonsteroidal Anti-inflammatory Drugs
    • Naproxen
    • Aspirin
    • Diclofenac
    • Ibuprofen
    • Other NSAIDs
  • Analgesics
    • Duloxetine
    • Acetaminophen
  • Corticosteroids 

Osteoarthritis Therapeutics by Route of Administration

  • Parenteral Route
  • Topical Route
  • Oral Route 

Osteoarthritis Therapeutics by Purchasing Pattern

  • Prescription Drugs
  • Over-the-Counter Drugs

Osteoarthritis Therapeutics Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Osteoarthritis Therapeutics Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • Middle East & Africa 

Key developments:

  • In 2020, GlaxoSmithKline Plc (UK) launched Voltaren in the US.
  • In 2020, Horizon Therapeutics Plc (Ireland) expanded its presence in the US.
  • In 2019, Kitov Pharma Ltd. (Israel) entered into an agreement with Coeptis Pharmaceuticals which has helped in the efficient distribution and commercialization of Consensi.
  • In 2018, Atnahs established a sales office in Dubai, UAE.
  • In 2017, Flexion Therapeutics, Inc. (US) received FDA Approval for ZILRETTA 

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 31)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
          1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
          1.3.1 MARKETS COVERED
          1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES
    1.8 LIMITATIONS OF THE CURRENT EDITION

2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA
        FIGURE 1 RESEARCH DESIGN
          2.1.1 SECONDARY DATA
                   2.1.1.1 Key data from secondary sources
          2.1.2 PRIMARY DATA
                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                   2.1.2.1 Key data from primary sources
    2.2 MARKET SIZE ESTIMATION
        FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
          2.2.1 BOTTOM-UP APPROACH
                FIGURE 4 OSTEOARTHRITIS THERAPEUTICS MARKET: BOTTOM-UP APPROACH
          2.2.2 GROWTH FORECAST
          2.2.3 TOP-DOWN APPROACH
                FIGURE 5 OSTEOARTHRITIS THERAPEUTICS MARKET: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
        FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 43)
  FIGURE 7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020 VS. 2025 (USD BILLION) 43
  FIGURE 8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020 VS. 2025 (USD BILLION) 44
  FIGURE 9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD BILLION)
  FIGURE 10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020 VS. 2025 (USD BILLION)
  FIGURE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2020 VS. 2025 (USD BILLION) 46
  FIGURE 12 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2020 VS. 2025 (USD BILLION) 47

4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 OSTEOARTHRITIS THERAPEUTICS MARKET OVERVIEW
        FIGURE 13 INCREASING PREVALENCE OF OSTEOARTHRITIS IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET
    4.2 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY DRUG TYPE (2019)
        FIGURE 14 VISCOSUPPLEMENTATION AGENTS SEGMENT TO DOMINATE THE EUROPEAN MARKET IN 2020
    4.3 GEOGRAPHICAL SNAPSHOT OF THE OSTEOARTHRITIS THERAPEUTICS MARKET
        FIGURE 15 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD IN THE OSTEOARTHRITIS THERAPEUTICS MARKET 50

5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 16 OSTEOARTHRITIS THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          5.2.1 DRIVERS
                   5.2.1.1 Significant adoption of pain medications
                   5.2.1.2 Increasing prevalence of osteoarthritis
                   5.2.1.3 Growing population susceptible to osteoarthritis
                           FIGURE 17 SHARE OF OBESE ADULTS, BY REGION (2016)
                   5.2.1.4 Rising number of sports injuries
                           FIGURE 18 INJURIES CAUSED BY SPORTS ACTIVITIES IN THE US (2019)
          5.2.2 RESTRAINTS
                   5.2.2.1 Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment
                   5.2.2.2 Commercialization of alternatives
          5.2.3 OPPORTUNITIES
                   5.2.3.1 Personalized medicines for osteoarthritis
                   5.2.3.2 Emerging markets
                   5.2.3.3 Collaborations for product development
          5.2.4 CHALLENGES
                   5.2.4.1 Adoption of non-drug pain management therapies
    5.3 VALUE CHAIN ANALYSIS
        FIGURE 19 VALUE CHAIN ANALYSIS: PHARMACEUTICALS INDUSTRY
        TABLE 1 COSTS INCURRED AND VALUE ADDED ACROSS THE VALUE CHAIN, BY COMPONENT
    5.4 SUPPLY CHAIN ANALYSIS
        FIGURE 20 DIRECT DISTRIBUTION-THE PREFERRED STRATEGY OF PROMINENT COMPANIES
    5.5 ECOSYSTEM ANALYSIS
        FIGURE 21 ECOSYSTEM ANALYSIS
    5.6 COVID-19 IMPACT ANALYSIS ON THE OSTEOARTHRITIS THERAPEUTICS MARKET
    5.7 AVERAGE SELLING PRICE TREND
        TABLE 2 AVERAGE SELLING PRICE OF OSTEOARTHRITIS DRUGS
    5.8 REGULATORY SCENARIO
        TABLE 3 LIST OF REGULATORY AUTHORITIES IN THE PHARMA INDUSTRY
          5.8.1 REGULATORY REQUIREMENTS
                   5.8.1.1 EU regulations
                   5.8.1.2 US regulations
    5.9 EPIDEMIOLOGY (PATIENT POPULATION)
          5.9.1 SEVERITY
                TABLE 4 COUNTRY-WISE OSTEOARTHRITIS EPIDEMIOLOGY, BY SEVERITY (2019)
          5.9.2 ANATOMY
                TABLE 5 COUNTRY-WISE OSTEOARTHRITIS EPIDEMIOLOGY, BY ANATOMY (2019)

6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY (Page No. - 67)
    6.1 INTRODUCTION
        TABLE 6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    6.2 KNEE OSTEOARTHRITIS
          6.2.1 RISING OBESE AND GERIATRIC POPULATIONS TO INCREASE THE PREVALENCE OF KNEE OSTEOARTHRITIS
                TABLE 7 KNEE OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
    6.3 HIP OSTEOARTHRITIS
          6.3.1 SIMILAR TO KNEE OSTEOARTHRITIS, HIP OSTEOARTHRITIS IS MORE COMMON IN THE GERIATRIC AND OBESE POPULATIONS
                TABLE 8 HIP OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
    6.4 HAND OSTEOARTHRITIS
          6.4.1 RISING PREVALENCE OF SHOULDER OSTEOARTHRITIS TO DRIVE MARKET GROWTH
                TABLE 9 HAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
    6.5 SMALL JOINT OSTEOARTHRITIS
          6.5.1 RISING NUMBER OF ANKLE-RELATED SPORTS INJURIES TO INCREASE THE PREVALENCE OF ANKLE OSTEOARTHRITIS
                TABLE 10 SMALL JOINT OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
 
7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE (Page No. - 72)
    7.1 INTRODUCTION
        TABLE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    7.2 VISCOSUPPLEMENTATION AGENTS
          7.2.1 VISCOSUPPLEMENTATION AGENTS DOMINATED THE MARKET IN 2019
                TABLE 12 OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2018-2025 (USD MILLION)
    7.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
          7.3.1 NSAIDS CAN RELIEVE PAIN AND INFLAMMATION WITHOUT THE ADVERSE EFFECTS OF CORTICOSTEROIDS
                TABLE 13 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                TABLE 14 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2025 (USD MILLION)
                   7.3.1.1 Ibuprofen
                           TABLE 15 OSTEOARTHRITIS THERAPEUTICS MARKET FOR IBUPROFEN, BY REGION, 2018-2025 (USD MILLION)
                   7.3.1.2 Aspirin
                           TABLE 16 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ASPIRIN, BY REGION, 2018-2025 (USD MILLION)
                   7.3.1.3 Diclofenac
                           TABLE 17 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DICLOFENAC, BY REGION, 2018-2025 (USD MILLION)
                   7.3.1.4 Naproxen
                           TABLE 18 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NAPROXEN, BY REGION, 2018-2025 (USD MILLION)
                   7.3.1.5 Other NSAIDs
                           TABLE 19 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OTHER NSAIDS, BY REGION, 2018-2025 (USD MILLION)
    7.4 ANALGESICS
          7.4.1 ACETAMINOPHEN HOLDS THE LARGEST SHARE OF THE ANALGESICS MARKET
                TABLE 20 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                TABLE 21 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION, 2018-2025 (USD MILLION)
                   7.4.1.1 Acetaminophen
                           TABLE 22 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ACETAMINOPHEN, BY REGION, 2018-2025 (USD MILLION)
                   7.4.1.2 Duloxetine
                           TABLE 23 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DULOXETINE, BY REGION, 2018-2025 (USD MILLION)
    7.5 CORTICOSTEROIDS
          7.5.1 EUROPE AND NORTH AMERICA ARE THE LARGEST MARKETS FOR CORTICOSTEROIDS
                TABLE 24 OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2018-2025 (USD MILLION)

8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 81)
    8.1 INTRODUCTION
        TABLE 25 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    8.2 PARENTERAL ROUTE
          8.2.1 DRUGS INEFFECTIVE WHEN ADMINISTERED ORALLY CAN BE DELIVERED VIA PARENTERAL ROUTE
                TABLE 26 PARENTERAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
    8.3 ORAL ROUTE
          8.3.1 ORAL ROUTE IS WIDELY PREFERRED BY BOTH CLINICIANS AND PATIENTS
                TABLE 27 ORAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
    8.4 TOPICAL ROUTE
          8.4.1 EASE OF USE, PAINLESS AND NON-INVASIVE ADMINISTRATION HAVE SUPPORTED USE OF TOPICAL ROUTE
                TABLE 28 TOPICAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)

9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL (Page No. - 85)
    9.1 INTRODUCTION
        TABLE 29 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    9.2 HOSPITAL PHARMACIES
          9.2.1 HOSPITAL PHARMACIES ARE THE LARGEST DISTRIBUTION CHANNEL FOR OSTEOARTHRITIS THERAPEUTICS
                TABLE 30 OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2018-2025 (USD MILLION)
    9.3 RETAIL PHARMACIES
          9.3.1 GREATER PREFERENCE FOR RETAIL PHARMACIES HAS AFFECTED MARKET SHARE
                TABLE 31 OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2018-2025 (USD MILLION)
    9.4 ONLINE PHARMACIES
          9.4.1 ONLINE PHARMACIES TO REGISTER THE HIGHEST GROWTH
                TABLE 32 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2018-2025 (USD MILLION)

10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN (Page No. - 89)
     10.1 INTRODUCTION
          TABLE 33 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
     10.2 PRESCRIPTION DRUGS
            10.2.1 PRESCRIPTION DRUGS TO ACCOUNT FOR A LARGER SHARE OF THE MARKET
                   TABLE 34 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2018-2025 (USD MILLION)
     10.3 OVER-THE-COUNTER DRUGS
            10.3.1 EASE OF PURCHASE AND ADMINISTRATION ARE RESULTING IN A RISING DEMAND FOR OTC DRUGS
                   TABLE 35 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2018-2025 (USD MILLION)

11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION (Page No. - 92)
     11.1 INTRODUCTION
          TABLE 36 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
     11.2 EUROPE
          FIGURE 22 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
          TABLE 37 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
          TABLE 38 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
          TABLE 39 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
          TABLE 40 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 41 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
          TABLE 42 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
          TABLE 43 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
          TABLE 44 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.2.1 ITALY
                     11.2.1.1 Italy dominates the European market for osteoarthritis therapeutics
                              TABLE 45 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 46 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 47 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 48 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 49 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 50 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 51 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.2.2 GERMANY
                     11.2.2.1 Road accidents in the country to propel the demand for osteoarthritis therapeutics
                              TABLE 52 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 53 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 54 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 55 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 56 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 57 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 58 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.2.3 SPAIN
                     11.2.3.1 High prevalence of osteoarthritis to drive the growth of the market
                              TABLE 59 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 60 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 61 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 62 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 63 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 64 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 65 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.2.4 FRANCE
                     11.2.4.1 Rising geriatric population to accelerate the growth of the market during the forecast period
                              TABLE 66 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 67 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 68 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 69 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 70 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 71 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 72 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.2.5 UK
                     11.2.5.1 Increasing obesity rate and rising incidence of musculoskeletal diseases drive the market in the UK
                              TABLE 73 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 74 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 75 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 76 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 77 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 78 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 79 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.2.6 REST OF EUROPE
                   TABLE 80 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                   TABLE 81 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                   TABLE 82 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 83 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                   TABLE 84 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                   TABLE 85 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                   TABLE 86 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
     11.3 NORTH AMERICA
          TABLE 87 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
          TABLE 88 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
          TABLE 89 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
          TABLE 90 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 91 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
          TABLE 92 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
          TABLE 93 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
          TABLE 94 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.3.1 US
                     11.3.1.1 The US holds the largest share in the North American market
                              TABLE 95 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 96 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 97 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 98 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 99 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 100 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 101 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.3.2 CANADA
                     11.3.2.1 Rising geriatric and obese populations will drive the incidence of osteoarthritis therapeutics
                              TABLE 102 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 103 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 104 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 105 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 106 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 107 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 108 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
     11.4 ASIA PACIFIC
          FIGURE 23 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
          TABLE 109 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
          TABLE 110 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
          TABLE 111 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
          TABLE 112 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 113 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
          TABLE 114 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
          TABLE 115 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
          TABLE 116 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.4.1 JAPAN
                     11.4.1.1 Japan dominates the osteoarthritis therapeutics market in the APAC
                              TABLE 117 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 118 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 119 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 120 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 121 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 122 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 123 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.4.2 CHINA
                     11.4.2.1 Rising geriatric population to propel the demand for osteoarthritis therapeutics in China
                              TABLE 124 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 125 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 126 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 127 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 128 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 129 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 130 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.4.3 INDIA
                     11.4.3.1 Rising prevalence of osteoarthritis to accelerate market growth in India
                              TABLE 131 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 132 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 133 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 134 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 135 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 136 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 137 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.4.4 SOUTH KOREA
                     11.4.4.1 Initiatives by market players to support the growth of the market
                              TABLE 138 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 139 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 140 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 141 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 142 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 143 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 144 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.4.5 AUSTRALIA
                     11.4.5.1 Prevalence of osteoarthritis to accelerate the growth of the market
                              TABLE 145 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 146 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 147 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 148 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 149 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 150 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 151 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.4.6 REST OF ASIA PACIFIC
                   TABLE 152 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                   TABLE 153 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                   TABLE 154 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 155 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                   TABLE 156 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                   TABLE 157 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                   TABLE 158 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
     11.5 REST OF THE WORLD
          TABLE 159 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
          TABLE 160 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
          TABLE 161 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
          TABLE 162 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 163 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
          TABLE 164 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
          TABLE 165 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
          TABLE 166 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.5.1 LATIN AMERICA
                     11.5.1.1 Latin America holds a larger share of the RoW market
                              TABLE 167 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 168 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 169 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 170 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 171 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 172 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 173 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
            11.5.2 MIDDLE EAST AND AFRICA
                     11.5.2.1 Rising obesity rates to propel market growth
                              TABLE 174 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
                              TABLE 175 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
                              TABLE 176 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
                              TABLE 177 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
                              TABLE 178 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
                              TABLE 179 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
                              TABLE 180 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE & COMPANY PROFILES (Page No. - 148)
     12.1 COMPETITIVE LANDSCAPE
            12.1.1 OVERVIEW
                   FIGURE 24 KEY DEVELOPMENTS IN THE OSTEOARTHRITIS THERAPEUTICS MARKET, JANUARY 2017-NOVEMBER 2020
                   FIGURE 25 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO NOVEMBER 2020
            12.1.2 COMPETITIVE SCENARIO
                     12.1.2.1 Product launches and approvals
                              TABLE 181 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017?NOVEMBER 2020
                     12.1.2.2 Collaborations and agreements
                              TABLE 182 KEY COLLABORATIONS AND AGREEMENTS, JANUARY 2017?NOVEMBER 2020
                     12.1.2.3 Expansions
                              TABLE 183 KEY EXPANSIONS, JANUARY 2017?NOVEMBER 2020
                     12.1.2.4 Mergers and acquisitions
                              TABLE 184 KEY MERGERS AND ACQUISITIONS, JANUARY 2017?NOVEMBER 2020
                     12.1.2.5 Other developments
                              TABLE 185 OTHER DEVELOPMENTS, JANUARY 2017?NOVEMBER 2020
            12.1.3 VISCOSUPPLEMENTATION AGENTS MARKET SHARE ANALYSIS, 2019
                   FIGURE 26 VISCOSUPPLEMENTATION AGENTS MARKET SHARE ANALYSIS, 2019
            12.1.4 COMPANY EVALUATION MATRIX
                     12.1.4.1 Stars
                     12.1.4.2 Emerging leaders
                     12.1.4.3 Pervasive companies
                     12.1.4.4 Participants
                              FIGURE 27 OSTEOARTHRITIS THERAPEUTICS MARKET (GLOBAL) COMPANY EVALUATION MATRIX, 2019
     12.2 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, SWOT analysis, MNM view)*
            12.2.1 PFIZER, INC.
                   FIGURE 28 PFIZER, INC.: COMPANY SNAPSHOT (2019)
            12.2.2 HORIZON THERAPEUTICS PLC
                   FIGURE 29 HORIZON THERAPEUTICS PLC: COMPANY SNAPSHOT (2019)
            12.2.3 SANOFI
                   FIGURE 30 SANOFI: COMPANY SNAPSHOT (2019)
            12.2.4 JOHNSON & JOHNSON
                   FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
            12.2.5 BAYER AG
                   FIGURE 32 BAYER AG: COMPANY SNAPSHOT (2019)
            12.2.6 ABBOTT
                   FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2019)
            12.2.7 GLAXOSMITHKLINE PLC
                   FIGURE 34 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
            12.2.8 ZIMMER BIOMET HOLDINGS
                   FIGURE 35 ZIMMER BIOMET HOLDINGS, INC.: COMPANY SNAPSHOT (2019)
            12.2.9 NOVARTIS AG
                   FIGURE 36 NOVARTIS: COMPANY SNAPSHOT (2019)
            12.2.10 FLEXION THERAPEUTICS, INC.
                   FIGURE 37 FLEXION THERAPEUTICS: COMPANY SNAPSHOT (2019)
            12.2.11 ANIKA THERAPEUTICS
                   FIGURE 38 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2019)
            12.2.12 ELI LILLY
                   FIGURE 39 ELI LILLY: COMPANY SNAPSHOT (2019)
            12.2.13 HANMI PHARM. CO., LTD.
                   FIGURE 40 HANMI PHARM.CO., LTD.: COMPANY SNAPSHOT (2019)
            12.2.14 ASSERTIO THERAPEUTICS, INC.
                   FIGURE 41 ASSERTIO THERAPEUTICS: COMPANY SNAPSHOT (2019)
            12.2.15 LABORATORIO REIG JOFRE
                   FIGURE 42 LABORATORIO REIG JOFRE: COMPANY SNAPSHOT (2019)
            12.2.16 KITOV PHARMACEUTICALS
                   FIGURE 43 KITOV PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2019)
            12.2.17 VIRCHOW BIOTECH
            12.2.18 FERRING PHARMACEUTICALS
            12.2.19 BIOVENTUS
            12.2.20 ALMATICA PHARMA LLC
            12.2.21 ATNAHS
            12.2.22 PHARMED LIMITED
            12.2.23 ORTHOGENRX
            12.2.24 LABRHA
            12.2.25 FIDIA FARMACEUTICI S.P.A.

*Details on Business overview, Products offered, Recent Developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 192)
     13.1 INDUSTRY INSIGHTS
     13.2 DISCUSSION GUIDE
     13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
     13.4 AVAILABLE CUSTOMIZATIONS
     13.5 RELATED REPORTS
     13.6 AUTHOR DETAILS

The study involved four major activities to estimate the current size of the osteoarthritis therapeutics market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.

Primary Research

Several stakeholders such as osteoarthritis therapeutics manufacturers, vendors, distributors, researchers, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by significant use of osteoarthritis therapeutics due to , significant adoption of pain medications, increasing prevalence of osteoarthritis, growing population susceptible to osteoarthritis, and rising number of sports injuries. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

BREAKDOWN OF PRIMARY PARTICIPANTS:

Osteoarthritis Therapeutics Market Size

To know about the assumptions considered for the study, download the pdf brochure

Note 1: C-level primaries include chief executive officers (CEOs), chief operation officers (COOs), and chief financial officers (CFOs). D-level primaries include directors, managers, and heads of departments. Others include sales managers, marketing managers, and product managers.

Note 2: Company tiers are defined on the basis of their total revenues for 2019. Tier 1= >USD 1,000 million, Tier 2= USD 100 million to USD 1,000 million, and Tier 3=

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the osteoarthritis therapeutics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources 

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the osteoarthritis therapeutics industry.

Report Objectives 

  • To define, describe, and forecast the osteoarthritis therapeutics market on the basis of product, cell type, process, end user, and region.
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities, Covid-19 Impact Analysis)
  • To strategically analyse micromarkets with respect to individual growth trends, prospects, and contributions to the overall osteoarthritis therapeutics market
  • To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in four geographical regions, namely, North America, Europe, the Asia Pacific, and Rest of the World.
  • To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies.
  • To track and analyse competitive developments such as product launches and approvals, partnerships, expansions, and acquisitions in the osteoarthritis therapeutics market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis:

  • Further breakdown of the osteoarthritis therapeutics market into specific countries/regions in the Rest of Europe and the Rest of Asia Pacific.

Company Information:

  • Detailed analysis and profiling of additional market players (up to 3) inclusive of:
    • Business Overview
    • Financial Information
    • Product Portfolio
    • Developments (last three years)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Osteoarthritis Therapeutics Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Osteoarthritis Therapeutics Market

Request For Special Pricing
Report Code
PH 7393
Published ON
Dec, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Osteoarthritis Therapeutics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved